{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:17:30Z","timestamp":1792700250215,"version":"4.5.0"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.cca.2026.121260","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:49:29Z","timestamp":1786463369000},"page":"121260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["suPAR as a circulating inflammatory biomarker: time for translation into clinical practice \u2013 A systematic review"],"prefix":"10.1016","volume":"593","author":[{"given":"Filomena","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Montuori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.121260_bb0005","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med."},{"key":"10.1016\/j.cca.2026.121260_bb0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41398-019-0570-y","article-title":"Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses","volume":"9","author":"Yuan","year":"2019","journal-title":"Transl Psychiatry."},{"key":"10.1016\/j.cca.2026.121260_bb0015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3390\/jcm10030518","article-title":"The role of the plasminogen activation system in angioedema: novel insights on the pathogenesis","volume":"10","author":"Napolitano","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.cca.2026.121260_bb0020","first-page":"7126","article-title":"Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy","volume":"60","author":"Mustjoki","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2026.121260_bb0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2796.2010.02284.x","article-title":"Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening","volume":"269","author":"Kjellman","year":"2011","journal-title":"J Intern Med."},{"key":"10.1016\/j.cca.2026.121260_bb0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4137\/BMI.S8326","article-title":"Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels","volume":"6","author":"Gustafsson","year":"2011","journal-title":"Biomark Insights"},{"key":"10.1016\/j.cca.2026.121260_bb0035","first-page":"3294","article-title":"Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer","volume":"58","author":"Wahlberg","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2026.121260_bb0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/antibiotics13020179","article-title":"Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection","volume":"13","author":"Klim","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cca.2026.121260_bb0045","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10096-011-1423-7","article-title":"Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome","volume":"31","author":"Tzanakaki","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.cca.2026.121260_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780641","article-title":"Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation","volume":"12","author":"Rasmussen","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0055","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0021-9258(18)52382-6","article-title":"Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol","volume":"266","author":"Ploug","year":"1991","journal-title":"J Biol Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0060","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1016\/S0021-9258(18)31492-3","article-title":"A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor","volume":"266","author":"Masucci","year":"1991","journal-title":"J Biol Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0065","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood.V79.6.1447.1447","article-title":"The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria","volume":"79","author":"Ploug","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121260_bb0070","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.1995.tb08366.x","article-title":"The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria","volume":"89","author":"R\u00f8nne","year":"1995","journal-title":"Br J Haematol."},{"key":"10.1016\/j.cca.2026.121260_bb0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0925-5710(96)00559-2","article-title":"Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity","volume":"65","author":"Ninomiya","year":"1997","journal-title":"Int J Hematol."},{"key":"10.1016\/j.cca.2026.121260_bb0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cell.2024.10.045","article-title":"Atlas of the plasma proteome in health and disease in 53,026 adults","volume":"188","author":"Deng","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.cca.2026.121260_bb0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/j.1460-2075.1990.tb08132.x","article-title":"Cloning and expression of the receptor for human urokinase plasminogen activator","volume":"9","author":"Roldan","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/j.cca.2026.121260_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.818616","article-title":"Modulation of cellular function by uPAR signalling: a mechanistic view","volume":"10","author":"Alfano","year":"2022","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.cca.2026.121260_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1016\/j.cca.2026.121260_bb0100","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1121143","article-title":"Structure of human urokinase plasminogen activator in complex with its receptor","volume":"311","author":"Huai","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.cca.2026.121260_bb0105","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.3390\/cancers17203309","article-title":"The urokinase-type plasminogen activator receptor as a mediator of physiological and pathological processes","volume":"17","author":"Iftikhar","year":"2025","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.cca.2026.121260_bb0110","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/ijms24021796","article-title":"The uPA\/uPAR System Orchestrates the Inflammatory Response, Vascular Homeostasis, and Immune System in Fibrosis Progression","volume":"24","author":"Kanno","year":"2023","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.cca.2026.121260_bb0115","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3390\/ijms23116065","article-title":"Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications","volume":"23","author":"Napolitano","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.cca.2026.121260_bb0120","first-page":"34","article-title":"The urokinase\/urokinase receptor system in mast cells: effects of its functional interaction with fMLF receptors","volume":"15","author":"Rossi","year":"2016","journal-title":"Transl Med UniSa."},{"key":"10.1016\/j.cca.2026.121260_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.818616","article-title":"Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View","volume":"10","author":"Alfano","year":"2022","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.cca.2026.121260_bb0130","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.3390\/ijms22084111","article-title":"The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications","volume":"22","author":"Li Santi","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.cca.2026.121260_bb0135","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1083\/jcb.200702151","article-title":"Monomer dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies","volume":"179","author":"Caiolfa","year":"2007","journal-title":"J Cell Biol."},{"key":"10.1016\/j.cca.2026.121260_bb0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nsmb.1404","article-title":"Crystal structures of uPAR complexes","volume":"15","author":"Huai","year":"2008","journal-title":"Nat Struct Mol Biol."},{"key":"10.1016\/j.cca.2026.121260_bb0145","doi-asserted-by":"crossref","first-page":"32380","DOI":"10.1016\/S0021-9258(18)31646-6","article-title":"Identification of uPAR as vitronectin receptor","volume":"269","author":"Wei","year":"1994","journal-title":"J Biol Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0150","doi-asserted-by":"crossref","first-page":"24792","DOI":"10.1074\/jbc.M413954200","article-title":"Domain 2 of uPAR contains integrin-interacting epitope","volume":"280","author":"Degryse","year":"2005","journal-title":"J Biol Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0155","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1074\/jbc.M512311200","article-title":"uPAR domain III controls integrin interaction and tumor growth","volume":"281","author":"Chaurasia","year":"2006","journal-title":"J Biol Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0160","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.4049\/jimmunol.1402819","article-title":"Upregulation of N-formyl peptide receptors in scleroderma fibroblasts","volume":"194","author":"Rossi","year":"2015","journal-title":"J Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0165","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3389\/fimmu.2018.00574","article-title":"N-formyl peptide receptors induce radical oxygen production in fibroblasts derived from systemic sclerosis by interacting with a cleaved form of urokinase receptor","volume":"9","author":"Napolitano","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0170","doi-asserted-by":"crossref","first-page":"1568629","DOI":"10.3389\/fimmu.2025.1568629","article-title":"The N-formyl peptide receptors: much more than chemoattractant receptors","volume":"16","author":"Napolitano","year":"2025","journal-title":"Relevance in health and disease, Front Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: the molecular crystal ball","volume":"27","author":"Thun\u00f8","year":"2009","journal-title":"Dis. Markers"},{"key":"10.1016\/j.cca.2026.121260_bb0180","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s13054-020-03336-0","article-title":"Plasma levels of the active form of suPAR are associated with COVID-19 severity","volume":"24","author":"Huang","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.cca.2026.121260_bb0185","doi-asserted-by":"crossref","first-page":"27982","DOI":"10.1074\/jbc.M111736200","article-title":"urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization","volume":"277","author":"Sidenius","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0190","doi-asserted-by":"crossref","first-page":"2068691","DOI":"10.1155\/2016\/2068691","article-title":"soluble urokinase receptors in focal segmental glomerulosclerosis: a review on the scientific point of view","volume":"2016","author":"Kronbichler","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cca.2026.121260_bb0195","doi-asserted-by":"crossref","first-page":"13647","DOI":"10.1038\/srep13647","article-title":"Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes","volume":"5","author":"Alfano","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121260_bb0200","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.3390\/ijms25063156","article-title":"The crosstalk between N-formyl peptide receptors and uPAR in systemic sclerosis: molecular mechanisms, pathogenetic role and therapeutic opportunities","volume":"25","author":"Napolitano","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121260_bb0205","article-title":"suPAR, a circulating kidney disease factor","volume":"8","author":"Wei","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.cca.2026.121260_bb0210","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s42003-021-02144-8","article-title":"Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor","volume":"4","author":"Dowsett","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.cca.2026.121260_bb0215","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41467-022-29344-y","article-title":"Crystal structure and cellular functions of uPAR dimer","volume":"13","author":"Yu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2026.121260_bb0220","doi-asserted-by":"crossref","first-page":"eabq6492","DOI":"10.1126\/scitranslmed.abq6492","article-title":"The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease","volume":"15","author":"Zhu","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0225","doi-asserted-by":"crossref","first-page":"1697785","DOI":"10.3389\/fimmu.2025.1697785","article-title":"Serum profiling of uPA, PAI-1, and suPAR in systemic sclerosis: a preliminary study on analytical aspects and associations with microvascular and fibrotic manifestations","volume":"16","author":"Napolitano","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40620-022-01344-7","article-title":"Assay-related differences in suPAR levels: implications for measurement and data interpretation","volume":"36","author":"Vasbinder","year":"2023","journal-title":"J. Nephrol."},{"key":"10.1016\/j.cca.2026.121260_bb0235","doi-asserted-by":"crossref","first-page":"13783","DOI":"10.1038\/s41598-019-50405-8","article-title":"Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis and impact of detection method","volume":"9","author":"Winnicki","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121260_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120303","article-title":"suPAR as a biomarker of support in different clinical settings","volume":"573","author":"Belvederi","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.121260_bb0245","doi-asserted-by":"crossref","unstructured":"C. Helena, T. Giulia, C. Alessandra, G. Roberto, S. Caterina, G. Sabrina, et al., Detection of inflammatory biomarker suPAR in COVID-19 disease with CHORUS TRIO instrument, Biomark. Insights 18 (2023) 11772719231210407.","DOI":"10.1177\/11772719231210407"},{"key":"10.1016\/j.cca.2026.121260_bb0250","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.talanta.2016.07.004","article-title":"An ELISA method detecting the active form of suPAR","volume":"160","author":"Zhou","year":"2016","journal-title":"Talanta"},{"key":"10.1016\/j.cca.2026.121260_bb0255","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12873-021-00544-x","article-title":"suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department","volume":"21","author":"Santeri","year":"2021","journal-title":"BMC Emerg. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0260","doi-asserted-by":"crossref","unstructured":"T.A. Skovsted, E.R.B. Petersen, M.B. Fruekilde, A.K. Pedersen, T. Pielak, J. Eugen-Olsen, validation of suPAR turbidimetric assay on Cobas\u00ae (c502 and c702) and comparison to suPAR ELISA, Scand. J. Clin. Lab. Invest. 80 (2020) 327\u2013335.","DOI":"10.1080\/00365513.2020.1741674"},{"key":"10.1016\/j.cca.2026.121260_bb0265","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1373\/clinchem.2004.038232","article-title":"Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor","volume":"50","author":"Piironen","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0270","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1373\/clinchem.2010.144410","article-title":"A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer","volume":"56","author":"Thurison","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0275","doi-asserted-by":"crossref","first-page":"35659","DOI":"10.1038\/s41598-025-19631-1","article-title":"Development of a serum protein biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma using a machine learning approach","volume":"15","author":"Shin","year":"2025","journal-title":"Sci Rep."},{"key":"10.1016\/j.cca.2026.121260_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120303","article-title":"suPAR as a biomarker of support in different clinical settings","volume":"573","author":"Belvederi","year":"2025","journal-title":"Clin Chim Acta."},{"key":"10.1016\/j.cca.2026.121260_bb0285","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clinbiochem.2019.05.010","article-title":"Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals","volume":"69","author":"Chew-Harris","year":"2019","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2026.121260_bb0290","article-title":"Establishing reference intervals for soluble urokinase plasminogen activator receptor in Northern European adults","volume":"39","author":"Bruun","year":"2024","journal-title":"Pract. Lab. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058506","article-title":"NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study","volume":"8","author":"Kruger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2026.121260_bb0300","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble urokinase receptor and chronic kidney disease","volume":"373","author":"Hayek","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4137\/BMI.S19876","article-title":"Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population","volume":"9","author":"Haupt","year":"2014","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.cca.2026.121260_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-018-0141-8","article-title":"Healthy lifestyles reduce suPAR and mortality in a Danish general population study","volume":"16","author":"Haupt","year":"2019","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.cca.2026.121260_bb0315","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000524433","article-title":"Soluble Urokinase Receptor Levels Are Not Affected by the Systemic Inflammatory Response to Anesthesia and Operative Trauma","volume":"63","author":"Laou","year":"2022","journal-title":"Eur Surg Res."},{"key":"10.1016\/j.cca.2026.121260_bb0320","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population","volume":"268","author":"Eugen-Olsen","year":"2010","journal-title":"J Intern Med."},{"key":"10.1016\/j.cca.2026.121260_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109091","article-title":"Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience","volume":"242","author":"Infantino","year":"2022","journal-title":"Clin Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0330","first-page":"3326","article-title":"Association of Preoperative Basal Inflammatory State, Measured by Plasma suPAR Levels, with Intraoperative Sublingual Microvascular Perfusion in Patients Undergoing Major Non-Cardiac Surgery, J","volume":"11","author":"Chalkias","year":"2022","journal-title":"Clin Med."},{"key":"10.1016\/j.cca.2026.121260_bb0335","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.it.2004.06.004","article-title":"uPA and uPAR in fibrinolysis, immunity and pathology","volume":"25","author":"Mondino","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0340","doi-asserted-by":"crossref","first-page":"12376","DOI":"10.3390\/ijms241512376","article-title":"Plasminogen System in the Pathophysiology of Sepsis: Upcoming Biomarkers","volume":"24","author":"Napolitano","year":"2023","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.cca.2026.121260_bb0345","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/emermed-2015-205444","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality A retrospective cohort study","volume":"33","author":"Rasmussen","year":"2016","journal-title":"Emerg Med J."},{"key":"10.1016\/j.cca.2026.121260_bb0350","doi-asserted-by":"crossref","unstructured":"F. Napolitano, G. Di Spigna, M. Vargas, C. Iacovazzo, B. Pinchera, D. Spalletti Cernia, et al., soluble urokinase receptor as a promising marker for early prediction of outcome in COVID-19 hospitalized patients, J. Clin. Med. 10 (2021) 4914.","DOI":"10.3390\/jcm10214914"},{"key":"10.1016\/j.cca.2026.121260_bb0355","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1478-3231.2011.02665.x","article-title":"Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis","volume":"32","author":"Zimmermann","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2026.121260_bb0360","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1515\/cclm-2022-0686","article-title":"Urokinase-type plasminogen activator soluble receptor (suPAR) assay in clinical routine: evaluation one year after its introduction in the high automation corelab of the A","volume":"61","author":"Sarlo","year":"2023","journal-title":"Gemelli hospital, Clin Chem Lab Med."},{"key":"10.1016\/j.cca.2026.121260_bb0365","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1046\/j.1523-1755.2001.00719.x","article-title":"release of urokinase plasminogen activator receptor during urosepsis and endotoxemia","volume":"59","author":"Florquin","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2026.121260_bb0370","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1469-0691.2004.00850.x","article-title":"The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality","volume":"10","author":"Wittenhagen","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.cca.2026.121260_bb0375","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/blood.V96.13.4091","article-title":"Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection","volume":"96","author":"Sidenius","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121260_bb0380","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00365540310017366","article-title":"soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome","volume":"36","author":"Ostergaard","year":"2004","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.cca.2026.121260_bb0385","doi-asserted-by":"crossref","first-page":"39481","DOI":"10.1038\/srep39481","article-title":"Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis","volume":"6","author":"Ni","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121260_bb0390","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s10096-011-1236-8","article-title":"elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia","volume":"30","author":"M\u00f6lk\u00e4nen","year":"2011","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.cca.2026.121260_bb0395","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2011.02363.x","article-title":"plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study","volume":"270","author":"Huttunen","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0400","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1038\/s41598-019-41688-y","article-title":"suPAR correlates with mortality and clinical severity in patients with necrotizing soft-tissue infections: results from a prospective observational cohort study","volume":"9","author":"Polzik","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121260_bb0405","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13054-024-04825-2","article-title":"qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial","volume":"28","author":"Adami","year":"2024","journal-title":"Crit. Care"},{"key":"10.1016\/j.cca.2026.121260_bb0410","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jmv.21114","article-title":"suPAR is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy","volume":"80","author":"Andersen","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cca.2026.121260_bb0415","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10096-007-0447-5","article-title":"predicting mortality in patients with systemic inflammatory response syndrome: evaluation of prognostic models and soluble receptors","volume":"27","author":"Kofoed","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.cca.2026.121260_bb0420","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QAD.0000000000004047","article-title":"biomarkers of microbial translocation and generalized inflammation are associated with frailty among people with HIV","volume":"39","author":"Ruderman","year":"2025","journal-title":"AIDS"},{"key":"10.1016\/j.cca.2026.121260_bb0425","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/hiv.12315","article-title":"soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study","volume":"17","author":"Rasmussen","year":"2016","journal-title":"HIV Med."},{"key":"10.1016\/j.cca.2026.121260_bb0430","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s13365-019-00775-6","article-title":"plasma (1\u21923)-\u03b2-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis","volume":"25","author":"Gianella","year":"2019","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.cca.2026.121260_bb0435","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/QAD.0000000000004103","article-title":"the relationship between immune markers and tryptophan-kynurenine metabolites in South African people with HIV","volume":"39","author":"Williams","year":"2025","journal-title":"AIDS"},{"key":"10.1016\/j.cca.2026.121260_bb0440","doi-asserted-by":"crossref","unstructured":"M. Hoenigl, C.B. Moser, N. Funderburg, R. Bosch, A. Kantor, Y. Zhang, et al., soluble urokinase plasminogen activator receptor is predictive of non-AIDS events during antiretroviral therapy-mediated viral suppression, Clin. Infect. Dis. 69 (2019) 676\u2013686.","DOI":"10.1093\/cid\/ciy966"},{"key":"10.1016\/j.cca.2026.121260_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070606","article-title":"HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression","volume":"8","author":"Nebuloni","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2026.121260_bb0450","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijtb.2017.01.012","article-title":"serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy","volume":"64","author":"Indumati","year":"2017","journal-title":"Indian J. Tuberc."},{"key":"10.1016\/j.cca.2026.121260_bb0455","article-title":"is analysis of inflammatory biomarkers and lymphocyte subpopulations useful in prediction of tuberculosis treatment outcomes?","volume":"25","author":"Musteikien\u0117","year":"2021","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"10.1016\/j.cca.2026.121260_bb0460","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/ijmy.ijmy_52_19","article-title":"soluble urokinase-type plasminogen activator receptor as a biomarker of treatment response in childhood tuberculosis","volume":"8","author":"Olivianto","year":"2019","journal-title":"Int. J. Mycobacteriol."},{"key":"10.1016\/j.cca.2026.121260_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.931321","article-title":"suPAR to risk-stratify patients with malaria","volume":"13","author":"Stefanova","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0470","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.0141-9838.2004.00695.x","article-title":"serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection","volume":"26","author":"Perch","year":"2004","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0475","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1086\/428854","article-title":"plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome","volume":"191","author":"Ostrowski","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cca.2026.121260_bb0480","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12936-016-1378-3","article-title":"plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children","volume":"15","author":"Tahar","year":"2016","journal-title":"Malar. J."},{"key":"10.1016\/j.cca.2026.121260_bb0485","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/diagnostics12020524","article-title":"specific combinations of inflammatory, angiogenesis and vascular integrity biomarkers are associated with clinical severity, coma and mortality in Beninese children with Plasmodium falciparum malaria","volume":"12","author":"Tornyigah","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cca.2026.121260_bb0490","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1475-2875-13-91","article-title":"correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria","volume":"13","author":"Plewes","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.cca.2026.121260_bb0495","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-3024.2006.00916.x","article-title":"elevated plasma urokinase receptor predicts low birth weight in maternal malaria","volume":"29","author":"Ostrowski","year":"2007","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.cca.2026.121260_bb0500","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0166-6851(97)02848-X","article-title":"host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes","volume":"86","author":"Roggwiller","year":"1997","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.cca.2026.121260_bb0505","article-title":"soluble urokinase plasminogen activator receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19","volume":"8","author":"Enocsson","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.cca.2026.121260_bb0510","doi-asserted-by":"crossref","unstructured":"I. Altintas, J. Eugen-Olsen, S. Sepp\u00e4l\u00e4, J. Tingleff, M.A. Stauning, N.O. El Caidi, et al., suPAR cut-offs for risk stratification in patients with symptoms of COVID-19, Biomark. Insights 16 (2021) 11772719211034685.","DOI":"10.1177\/11772719211034685"},{"key":"10.1016\/j.cca.2026.121260_bb0515","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1681\/ASN.2020060829","article-title":"soluble urokinase receptor (suPAR) in COVID-19-related AKI","volume":"31","author":"Azam","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2026.121260_bb0520","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13054-020-02897-4","article-title":"suPAR as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia","volume":"24","author":"Rovina","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.cca.2026.121260_bb0525","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0530","doi-asserted-by":"crossref","first-page":"3467690","DOI":"10.1155\/2019\/3467690","article-title":"increased serum soluble urokinase plasminogen activator receptor predicts short-term outcome in patients with hepatitis B-related acute-on-chronic liver failure","volume":"2019","author":"Huang","year":"2019","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.cca.2026.121260_bb0535","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s15010-023-02127-3","article-title":"soluble urokinase plasminogen activator receptor (suPAR) in bronchoalveolar fluid and blood in critically ill patients\u2014a prospective cohort study","volume":"52","author":"Reisinger","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.cca.2026.121260_bb0540","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/jpm13040688","article-title":"soluble urokinase plasminogen activator receptor (suPAR) in autoimmune rheumatic and non-rheumatic diseases","volume":"13","author":"Manfredi","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0545","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.trsl.2013.07.003","article-title":"soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus","volume":"162","author":"Enocsson","year":"2013","journal-title":"Transl. Res."},{"key":"10.1016\/j.cca.2026.121260_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102340","article-title":"soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus","volume":"106","author":"Enocsson","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cca.2026.121260_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100216","article-title":"suPAR and WT1 modify the adhesion of podocytes and are related to proteinuria in class IV lupus nephritis","volume":"7","author":"Bolla\u00edn-Y-Goytia","year":"2023","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.cca.2026.121260_bb0560","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10238-025-01897-4","article-title":"interferon alpha-induced uPAR expression on monocytes as a potential source of increased soluble uPAR in patients with SLE at high risk of developing organ damage","volume":"25","author":"Wirestam","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0565","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/1354750X.2021.1910343","article-title":"urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity","volume":"26","author":"Burcs\u00e1r","year":"2021","journal-title":"Biomarkers"},{"key":"10.1016\/j.cca.2026.121260_bb0570","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.trsl.2021.02.007","article-title":"serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlate with disease activity in early rheumatoid arthritis and reflect joint damage over time","volume":"232","author":"Enocsson","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.cca.2026.121260_bb0575","doi-asserted-by":"crossref","first-page":"176","DOI":"10.31083\/j.fbl2808176","article-title":"different biomarkers of response to treatment with selective JAK-1 inhibitors in rheumatoid arthritis","volume":"28","author":"Benucci","year":"2023","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.cca.2026.121260_bb0580","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12969-023-00832-9","article-title":"serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study","volume":"21","author":"Lewander","year":"2023","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"10.1016\/j.cca.2026.121260_bb0585","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1515\/cclm-2015-0079","article-title":"increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis","volume":"53","author":"Leg\u00e1ny","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0590","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247256","article-title":"association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis","volume":"16","author":"Butt","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2026.121260_bb0595","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/biom15091297","article-title":"assessment of cardiorenal involvement in systemic sclerosis patients","volume":"15","author":"Pellicano","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.cca.2026.121260_bb0600","first-page":"73","article-title":"Terzi, plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity","volume":"24","author":"Kurtipek","year":"2015","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat."},{"key":"10.1016\/j.cca.2026.121260_bb0605","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/1440-1681.13365","article-title":"suPAR, a potential inflammatory mediator in psoriasis pathogenesis","volume":"47","author":"Hamie","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.cca.2026.121260_bb0610","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/1756-185X.12873","article-title":"Terzi, plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Beh\u00e7et\u2019s disease and correlation with disease activity","volume":"21","author":"Saylam Kurtipek","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.cca.2026.121260_bb0615","doi-asserted-by":"crossref","first-page":"7850179","DOI":"10.1155\/2020\/7850179","article-title":"the plasma soluble urokinase plasminogen activator receptor is related to disease activity of patients with ANCA-associated vasculitis","volume":"2020","author":"Huang","year":"2020","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cca.2026.121260_bb0620","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.advms.2021.11.002","article-title":"anti-ETAR and suPAR as markers of disease activity in renal ANCA-associated vasculitis","volume":"67","author":"Rowaiye","year":"2022","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.cca.2026.121260_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2026.120831","article-title":"circulating suPAR as a noninvasive biomarker of fibrosis and immune activation in autoimmune liver diseases","volume":"583","author":"Zhan","year":"2026","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.121260_bb0630","doi-asserted-by":"crossref","first-page":"2183816","DOI":"10.1080\/10717544.2023.2183816","article-title":"quantitative analysis of therapeutic proteins in biological fluids: recent advancement in analytical techniques","volume":"30","author":"Song","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.cca.2026.121260_bb0635","first-page":"1293","article-title":"suPAR: a new biomarker for cardiovascular disease?","volume":"31","author":"Hodges","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.cca.2026.121260_bb0640","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.envres.2016.10.019","article-title":"cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease","volume":"152","author":"Fagerberg","year":"2017","journal-title":"Environ. Res."},{"key":"10.1016\/j.cca.2026.121260_bb0645","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/eci.12593","article-title":"plasma suPAR is lowered by smoking cessation: a randomized controlled study","volume":"46","author":"Eugen-Olsen","year":"2016","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.cca.2026.121260_bb0650","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1017\/S0007114518003720","article-title":"soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality","volume":"121","author":"T\u00f6rnkvist","year":"2019","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.cca.2026.121260_bb0655","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40618-020-01358-7","article-title":"plasma levels of soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein after Roux-en-Y gastric bypass or sleeve gastrectomy: a 1-year prospective observational study","volume":"44","author":"Kokkinos","year":"2021","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.cca.2026.121260_bb0660","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3390\/diagnostics13182938","article-title":"the association of suPAR with cardiovascular risk factors in young and healthy adults","volume":"13","author":"Wohlwend","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cca.2026.121260_bb0665","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5288","article-title":"racial discrimination and metabolic syndrome in young Black adults","volume":"7","author":"Heard-Garris","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cca.2026.121260_bb0670","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00431-024-05496-5","article-title":"soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study","volume":"183","author":"Kostopoulou","year":"2024","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.cca.2026.121260_bb0675","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jdiacomp.2019.06.001","article-title":"Khater, soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications","volume":"33","author":"Sherif","year":"2019","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.cca.2026.121260_bb0680","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036787","article-title":"inflammatory markers and measures of cardiovascular autonomic neuropathy in type 1 diabetes","volume":"14","author":"Ang","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.cca.2026.121260_bb0685","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008194","article-title":"predicting mortality in African Americans with type 2 diabetes mellitus: soluble urokinase plasminogen activator receptor, coronary artery calcium, and high-sensitivity C-reactive protein","volume":"7","author":"Hayek","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.cca.2026.121260_bb0690","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.acc.2024.04.005","article-title":"suPAR in cardiovascular disease","volume":"121","author":"Montecillo","year":"2024","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.cca.2026.121260_bb0695","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015452","article-title":"cardio-renal biomarker soluble urokinase-type plasminogen activator receptor is associated with cardiovascular death and myocardial infarction in patients with coronary artery disease independent of troponin, C-reactive protein, and renal function","volume":"9","author":"Nikorowitsch","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.cca.2026.121260_bb0700","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s11886-023-01991-7","article-title":"role of soluble urokinase-type plasminogen activator receptor in cardiovascular disease","volume":"25","author":"Ismail","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.cca.2026.121260_bb0705","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165868","article-title":"soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease","volume":"132","author":"Goodchild","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2026.121260_bb0710","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158788","article-title":"increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis","volume":"132","author":"Hindy","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.cca.2026.121260_bb0715","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population","volume":"268","author":"Eugen-Olsen","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0720","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2018.01.029","article-title":"Prognostic value of suPAR and hs-CRP on cardiovascular disease","volume":"271","author":"Diederichsen","year":"2018","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0725","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/STROKEAHA.113.003305","article-title":"Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease","volume":"45","author":"Persson","year":"2014","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.cca.2026.121260_bb0730","first-page":"1462","article-title":"suPAR predicts cardiovascular events and mortality in patients with asymptomatic aortic stenosis","volume":"32","author":"Hodges","year":"2016","journal-title":"Can. J. Cardiol."},{"issue":"4","key":"10.1016\/j.cca.2026.121260_bb0735","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2016.12.008","article-title":"Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure","volume":"5","author":"Koller","year":"2017","journal-title":"JACC Heart Fail."},{"issue":"4","key":"10.1016\/j.cca.2026.121260_bb0740","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jchf.2017.02.009","article-title":"Prognostic outcomes in patients with heart failure: a new suPAR biomarker for risk prediction?","volume":"5","author":"Pemberton","year":"2017","journal-title":"JACC Heart Fail."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0745","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41598-018-36960-6","article-title":"Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography","volume":"9","author":"Sommerer","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.cca.2026.121260_bb0750","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/2047487319885457","article-title":"Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort","volume":"27","author":"Frary","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.cca.2026.121260_bb0755","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1002\/ehf2.15423","article-title":"soluble urokinase plasminogen activator receptor and outcomes in HFpEF: a TOPCAT ancillary study","volume":"12","author":"Hutten","year":"2025","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.cca.2026.121260_bb0760","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.659524","article-title":"soluble urokinase plasminogen activator receptor is associated with subclinical myocardial impairment by speckle tracking echocardiography in lung cancer patients","volume":"8","author":"Manshad","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0765","doi-asserted-by":"crossref","DOI":"10.1172\/JCI197141","article-title":"The role of suPAR and related proteins in kidney, heart diseases, and diabetes","volume":"136","author":"Reiser","year":"2026","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0770","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor","volume":"14","author":"Wei","year":"2008","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.cca.2026.121260_bb0775","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.cca.2026.121260_bb0780","first-page":"300","article-title":"Circulating CD40 autoantibody and suPAR synergy drives glomerular injury","volume":"3","author":"Wei","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"8","key":"10.1016\/j.cca.2026.121260_bb0785","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1681\/ASN.2013040425","article-title":"Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice","volume":"25","author":"Cathelin","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0790","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/TP.0000000000002930","article-title":"Further evidence that the soluble urokinase plasminogen activator receptor does not directly injure mice or human podocytes","volume":"104","author":"Harel","year":"2020","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.cca.2026.121260_bb0795","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165740","article-title":"suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury","volume":"8","author":"Nusshag","year":"2023","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.cca.2026.121260_bb0800","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1911481","article-title":"Soluble urokinase receptor and acute kidney injury, N","volume":"382","author":"Hayek","year":"2020","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121260_bb0805","series-title":"prognostic significance of soluble urokinase-type plasminogen activator receptor in patients with glomerulonephritis: association with renal outcomes","author":"Choi","year":"2026"},{"issue":"12","key":"10.1016\/j.cca.2026.121260_bb0810","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2215\/CJN.0000000000000544","article-title":"Plasma biomarkers of kidney health and mortality in diabetes and chronic kidney disease in the REGARDS study","volume":"19","author":"Chen","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.cca.2026.121260_bb0815","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2215\/CJN.13631217","article-title":"Soluble urokinase-type plasminogen activator receptor in Black Americans with CKD","volume":"13","author":"Luo","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.cca.2026.121260_bb0820","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2017.2914","article-title":"Association of serum soluble urokinase receptor levels with progression of kidney disease in children","volume":"171","author":"Schaefer","year":"2017","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.cca.2026.121260_bb0825","doi-asserted-by":"crossref","first-page":"40627","DOI":"10.1038\/srep40627","article-title":"soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus","volume":"7","author":"Guthoff","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0830","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1681\/ASN.2020040487","article-title":"Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"32","author":"Schrauben","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.cca.2026.121260_bb0835","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2337\/dc18-1427","article-title":"soluble urokinase plasminogen activator receptor predicts cardiovascular events, kidney function decline, and mortality in patients with type 1 diabetes","volume":"42","author":"Rotbain Curovic","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cca.2026.121260_bb0840","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12872-026-05777-x","article-title":"from heart to kidney: FGF23, suPAR, and NAG as early biomarkers of cardiorenal syndrome in acute heart failure","volume":"26","author":"El-Desouki","year":"2026","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.cca.2026.121260_bb0845","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.xkme.2021.04.007","article-title":"variability in CKD biomarker studies: soluble urokinase plasminogen activator receptor (suPAR) and kidney disease progression in the Chronic Kidney Disease in Children (CKiD) study","volume":"3","author":"Abraham","year":"2021","journal-title":"Kidney Med."},{"key":"10.1016\/j.cca.2026.121260_bb0850","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.3390\/ijms22084111","article-title":"Ragno, the urokinase receptor: a multifunctional receptor in cancer cell biology. Therapeutic implications","volume":"22","author":"Li Santi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121260_bb0855","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.3390\/ijms241310519","article-title":"macrophages and urokinase plasminogen activator receptor system in multiple myeloma: case series and literature review","volume":"24","author":"Manzo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121260_bb0860","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/cancers14030498","article-title":"therapeutic strategies targeting urokinase and its receptor in cancer","volume":"14","author":"Masucci","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.121260_bb0865","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.646883","article-title":"serum levels of soluble urokinase plasminogen activator receptor predict tumor response and outcome to immune checkpoint inhibitor therapy","volume":"11","author":"Loosen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.121260_bb0870","doi-asserted-by":"crossref","first-page":"287","DOI":"10.17305\/bjbms.2022.7857","article-title":"assessment of clinical utility and predictive potential of pre-chemotherapy soluble urokinase plasminogen activator receptor: observational single center study","volume":"23","author":"Beleva","year":"2023","journal-title":"Biomol. Biomed."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0875","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00365521.2020.1849383","article-title":"plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer","volume":"56","author":"Aronen","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.cca.2026.121260_bb0880","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pan.2022.12.012","article-title":"plasma soluble urokinase-type plasminogen activator receptor (P-suPAR) in the diagnostics between malignant and non-malignant pancreatic lesions","volume":"23","author":"Aronen","year":"2023","journal-title":"Pancreatology"},{"issue":"8","key":"10.1016\/j.cca.2026.121260_bb0885","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/jso.25733","article-title":"the concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: a nationwide multicenter validation and discovery study","volume":"120","author":"Rolff","year":"2019","journal-title":"J. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2026.121260_bb0890","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.039728","article-title":"proteomics-based soluble urokinase plasminogen activator receptor levels and long-term cardiovascular outcomes in survivors of breast cancer: a UK Biobank study","volume":"14","author":"Yadalam","year":"2025","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0895","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13046-023-02876-x","article-title":"differential immunomodulatory effects of epirubicin\/cyclophosphamide and docetaxel in breast cancer patients","volume":"42","author":"Wimmer","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.cca.2026.121260_bb0900","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/CBM-220222","article-title":"circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response","volume":"39","author":"Setiawan","year":"2024","journal-title":"Cancer Biomark."},{"issue":"16","key":"10.1016\/j.cca.2026.121260_bb0905","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1017\/S0033291724002848","article-title":"cannabis use in youth is associated with chronic inflammation","volume":"54","author":"Power","year":"2024","journal-title":"Psychol. Med."},{"issue":"10","key":"10.1016\/j.cca.2026.121260_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110555","article-title":"soluble urokinase plasminogen activator receptor as a marker for use of antidepressants","volume":"9","author":"Haastrup","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2026.121260_bb0915","article-title":"suPAR in major depression: association with 26 weeks antidepressant response and 10-year depression outcomes","volume":"33","author":"Haupt","year":"2023","journal-title":"Brain Behav. Immun. Health"},{"issue":"Pt B","key":"10.1016\/j.cca.2026.121260_bb0920","article-title":"suPAR as a mediator between childhood trauma and adolescent depression","volume":"393","author":"Xie","year":"2026","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.cca.2026.121260_bb0925","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/jcpp.12928","article-title":"cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood","volume":"60","author":"Rasmussen","year":"2019","journal-title":"J. Child Psychol. Psychiatry"},{"key":"10.1016\/j.cca.2026.121260_bb0930","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbi.2025.02.020","article-title":"developmental stage of childhood trauma exposure and markers of inflammation at age 24","volume":"126","author":"Murphy","year":"2025","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0935","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jamapediatrics.2019.3875","article-title":"association of adverse experiences and exposure to violence in childhood and adolescence with inflammatory burden in young people","volume":"174","author":"Rasmussen","year":"2020","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.cca.2026.121260_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2025.107405","article-title":"inflammatory biomarkers and childhood maltreatment: a cluster analysis in patients with eating disorders","volume":"174","author":"Dani","year":"2025","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0945","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s12888-021-03522-6","article-title":"exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms","volume":"21","author":"Bigseth","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.cca.2026.121260_bb0950","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bbi.2024.06.003","article-title":"associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders \u2013 a systematic review and meta-analysis","volume":"120","author":"Murphy","year":"2024","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0955","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12017-026-08912-1","article-title":"soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker of neurodysfunction","volume":"28","author":"de Rezende","year":"2026","journal-title":"Neuromolecular Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0960","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/QAI.0000000000002924","article-title":"higher cerebrospinal fluid soluble urokinase-type plasminogen activator receptor, but not interferon \u03b3-inducible protein 10, correlates with higher working memory deficits","volume":"90","author":"De Almeida","year":"2022","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.cca.2026.121260_bb0965","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.bbi.2025.06.030","article-title":"executive function and soluble urokinase-type plasminogen activator receptor (suPAR): a longitudinal study of midlife adults","volume":"129","author":"Shell","year":"2025","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.cca.2026.121260_bb0970","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s10753-024-02185-1","article-title":"soluble urokinase-type plasminogen activator receptor and inflammatory biomarker response with prognostic significance after acute neuronal injury \u2013 a prospective cohort study","volume":"48","author":"Sajanti","year":"2025","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0975","doi-asserted-by":"crossref","first-page":"fcae475","DOI":"10.1093\/braincomms\/fcae475","article-title":"association of plasma soluble urokinase plasminogen activator receptor concentrations and migraine with aura: a REFORM study","volume":"7","author":"Tesfay","year":"2025","journal-title":"Brain Commun."},{"issue":"5","key":"10.1016\/j.cca.2026.121260_bb0980","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/10799893.2017.1328440","article-title":"the relationship between levels of plasma-soluble urokinase plasminogen activator receptor (suPAR) and presence of migraine attack and aura","volume":"37","author":"Y\u0131lmaz","year":"2017","journal-title":"J. Recept. Signal Transduct. Res."},{"issue":"1","key":"10.1016\/j.cca.2026.121260_bb0985","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s10194-025-02037-9","article-title":"plasma suPAR and therapeutic response to erenumab in migraine: a REFORM study","volume":"26","author":"Karlsson","year":"2025","journal-title":"J. Headache Pain"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126004420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126004420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:30Z","timestamp":1792081530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126004420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":197,"alternative-id":["S0009898126004420"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121260","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"suPAR as a circulating inflammatory biomarker: time for translation into clinical practice \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121260"}}